New cream may ease skin complications after stem cell transplant
NCT ID NCT03954236
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a cream containing ruxolitinib, a drug that targets inflammation, for treating a chronic skin condition called graft-versus-host disease (GVHD) that can occur after a stem cell transplant. About 24 participants will apply the cream to one side of their body and a standard moisturizer to the other, without knowing which is which. The goal is to see if the ruxolitinib cream safely reduces the affected skin area better than moisturizers alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SCLEROTIC CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States